Supplier News

BioVectra will open its new microbial fermentation and complex chemistry site, including the capability to handle high-potency APIs, by the end of 2017.

The company installed the FlexFactory to support its biosimilar production.

The company developed proxy-CRISPR which provides access to previously unreachable areas of the genome.

Thermo Fisher will acquire Patheon for approximately $7.2 billion, including the assumption of approximately $2 billion of net debt.

Catalent has signed an agreement with Therachon to support preclinical and clinical development of TA-46, a novel protein being developed to treat achondroplasia.

The partnership provides Charter Medical the exclusive rights to market, sell, and distribute INCELL media products on a global basis.

MilliporeSigma released a new surface-active nonionic polymer to ensure lot-to-lot consistency.

The company is the first multi-site excipient supplier to achieve accreditation across production facilities.

Operated by BioOutsource, Sartorius’ subsidiary, the Glasgow, UK-based service center will offer physicochemical properties and structural attributes testing and allow clients to perform structural and functional analyses in parallel.

Avid, a wholly owned subsidiary of Peregrine Pharmaceuticals, will upgrade its Myford, California clinical and commercial manufacturing facility with multiple Mobius 2000-L single-use bioreactors from MilliporeSigma, the companies announced on May 1, 2017.

United BioPharma Inc (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies in Hsinchu Industrial Park, Taiwan, the company announced on April 25, 2017. With this added capacity, UBP will support local healthcare needs by bringing biopharmaceuticals to the Taiwanese and surrounding markets faster.

Lonza revealed it received a warning letter from FDA for its cell therapy manufacturing plant.

The company is recalling one lot of 25% Dextrose injection after particulate matter was found within an internal sample syringe.

The company said it plans to invest $130 million in the United States and the United Kingdom to increase production capacity.

The funding allows the company to broaden its range of services and finance its move to new laboratory facilities in the Illkirch-Graffenstaden innovation park in northeast France.

Cobra will increase capacity in response to customer demand for DNA and viral vector production.

The two companies will develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis (NASH).

The company announced the expansion of its global shipping program, which now allows companies to ship dangerous goods between 36 countries.

GE Healthcare continues to ramp up its offerings in the bioprocessing space with the purchase of Asymptote and a continued partnership with Zenith Technologies.

MilliporeSigma’s new high-area cartridge filters and single-use capsules are suitable for feed streams with high levels of particulates.

Sartorius acquired the Swedish company that specializes in data analytics software for biopharmaceutical development and manufacturing.

The facility in Britley will now manufacture the company’s automated systems, enabling the company to better serve European markets and shorten the supply chain.

The Mobius MyWay portfolio offers off-the-shelf and configured-to-order single-use assemblies.

Permira will acquire LSNE, a CDMO for the pharmaceutical and medical device markets.

The company has invested in a new pharmaceutical chemistry and microbiology facility in Scotland.

Caladrius is selling the remaining percentage of the subsidiary in order to focus on cell therapy development.

The company announced that it would now be offering a portfolio of fresh and cryopreserved human and animal hepatocytes for ADME-Tox testing.

The ready-to-fill packaging solutions for vials are based on Ompi EZ-fill packaging design.

The company made a €42 million investment in a new building at its Reinbek site to support the production of biopharmaceuticals.

The new company links and manages aspects of treatment delivery, facilitating access for patients to treatments by serving as a connector between manufacturers, patients, physicians, and payors.